Evaluation of quality of life and its associations with clinical parameters in pediatric patients with familial Mediterranean fever

Deniz Gezgin Yildirim, Sevcan Azime Bakkaloglu, A Sebnem Soysal Acar, Bulent Celik, Necla Buyan, Deniz Gezgin Yildirim, Sevcan Azime Bakkaloglu, A Sebnem Soysal Acar, Bulent Celik, Necla Buyan

Abstract

Objective: A favorable quality of life (QoL) is important in children with chronic disease, and it reflects successful disease management. The aim of our study was to evaluate QoL and its association with clinical parameters in pediatric patients with familial Mediterranean fever (FMF).

Methods: The Kinder Lebensqualität Fragebogen (KINDL®) questionnaires (kiddy: 4-7 years; kid: 8-16 years) for children and the proxy version for parents were implemented as a QoL measure. A total of 171 FMF patients, 69 healthy peers and their parents were enrolled in the study.

Results: The KINDL QoL scores of the FMF patients were significantly lower than their healthy peers. The physical and emotional well-being KINDL QoL scores of the FMF children were significantly lower than their healthy peers (p=0.017 and p=0.020, respectively). In the evaluation of the KINDL QoL scores between the kiddy and kid groups, only the self-esteem score was higher in the kiddy group (p=0.004), and the school functioning scores were higher in the kid group (p=0.002). The scores in the physical well-being and disease module had significant differences between patients who were adherent and those who were non-adherent to colchicine therapy (p=0.042 and p=0.047, respectively). The scores in the physical well-being and disease module were significantly higher in patients with fewer attacks than those who had many attacks per year (p=0.004 and p=0.014, respectively).

Conclusion: This study suggests that FMF patients have significantly impaired QoL. The irregular use of colchicine and more frequent attacks affect QoL even more. A QoL assessment with multidisciplinary follow-up and control of the disease activity are essential, and if necessary, individualized support should be given to patients.

Keywords: Familial Mediterranean fever; pediatric rheumatology; quality of life.

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.

References

    1. Sarı İ, Birlik M, Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1:21–33.
    1. Ben-Chetrit E, Levy M. Colchicine:1998 update. Semin Arthritis Rheum. 1998;28:48–59.
    1. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever:a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265–71.
    1. Makay B, Unsal E, Arslan N, Varni JW. Health-related quality of life of school-age children with familial Mediterranean fever. Clin Exp Rheumatol. 2009;27:S96–101.
    1. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644–51.
    1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227–53.
    1. Pras E, Livneh A, Balow JE, Jr, Pras E, Kastner DL, Pras M, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75:216–9.
    1. Eser E, Yüksel H, Baydur H, Erhart M, Saatli G, Cengiz Ozyurt B, et al. The psychometric properties of the new Turkish generic health-related quality of life questionnaire for children (Kid-KINDL) Turk Psikiyatri Derg. 2008;19:409–17.
    1. Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol. 1997;15:355–60.
    1. Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, et al. Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci. 2013;17:958–63.
    1. Alayli G, Durmus D, Ozkaya O, Sen HE, Nalcacioglu H, Bilgici A, et al. Functional capacity, strength, and quality of life in children and youth with familial Mediterranean fever. Pediatr Phys Ther. 2014;26:347–52.
    1. Varan O, Kucuk H, Babaoglu H, Atas N, Salman RB, Satis H, et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clin Rheumatol. 2019;38:1125–30.
    1. Giese A, Kurucay M, Kilic L, Örnek A, Şendur SN, Lainka E, et al. Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects:a study evaluating the effect of disease severity and country of residence. Rheumatol Int. 2013;33:1713–9.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa